Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $37.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 335.80% from the stock’s previous close.

Pharming Group Price Performance

NASDAQ PHAR opened at $8.49 on Thursday. The company has a market cap of $571.76 million, a PE ratio of -53.06 and a beta of 0.14. Pharming Group has a 52-week low of $6.65 and a 52-week high of $13.40. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The firm’s 50 day moving average price is $7.79 and its 200-day moving average price is $8.89.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $74.09 million for the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same period in the previous year, the business earned $0.02 EPS. Sell-side analysts forecast that Pharming Group will post -0.15 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.